An Economic Evaluation of Sequential IV/po Moxifloxacin Therapy Compared to IV/po Co-amoxiclav With or Without Clarithromycin in the Treatment of Community-Acquired Pneumonia

This publication has 21 references indexed in Scilit:

• Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment
  Antimicrobial Agents and Chemotherapy, 2002
• Bismuth(III) Derivatives: New Catalysts
  Synlett, 2001
• Guidelines for the Management of Adults with Community-acquired Pneumonia
  American Journal of Respiratory and Critical Care Medicine, 2001
• Cost-effectiveness of Gatifloxacin vs Ceftriaxone With a Macrolide for the Treatment of Community-Acquired Pneumonia
  Chest, 2001
• COMMUNITY-ACQUIRED PNEUMONIA: EPIDEMIOLOGY, ETIOLOGY, TREATMENT
  Infectious Disease Clinics of North America, 1998
• Estimating country-specific cost-effectiveness from multinational clinical trials
  Health Economics, 1998
• ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society
  European Respiratory Journal, 1998
• Community-acquired pneumonia: the annual cost to the National Health Service in the UK
  European Respiratory Journal, 1997
• Should Clinical Trials With Concurrent Economic Analyses Be Blinded?
  JAMA, 1997
• Community-Acquired Pneumonia
  New England Journal of Medicine, 1995